glp-1 weight loss connecticut Investigational Dual GLP-1/GIP Agonist CT-388 Demonstrates 22.5% Placebo-Adjusted in Phase 2 Obesity Trial NutraBetic GLP-1 Companion, Supports GLP-1,

Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 4 June 2022, Ferruggia, Kennedy

He said many peptides are naturally occurring compounds that lack the patent protections needed to justify expensive clinical development programs

Poll: Roughly 12% of US Adults Have Used a GLP-1 Drug, Even If Unaffordable

It has accelerated interest in earlier intervention, vascular health strategies, exploring different GLP-1 formulations, and combination approaches that pair GLP-1s with complementary lifestyle or pharmacological synergists

Side Effect Profile: Side effect profiles vary by medication and may include gastrointestinal symptoms such as nausea or constipation